{"id":"https://openalex.org/W71283047","doi":null,"title":"Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.","display_name":"Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration.","publication_year":1999,"publication_date":"1999-01-01","ids":{"openalex":"https://openalex.org/W71283047","mag":"71283047","pmid":"https://pubmed.ncbi.nlm.nih.gov/9888428"},"language":"en","primary_location":{"id":"pmid:9888428","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9888428","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigative ophthalmology & visual science","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054939262","display_name":"Eti Yoles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I53964585","display_name":"Weizmann Institute of Science","ror":"https://ror.org/0316ej306","country_code":"IL","type":"education","lineage":["https://openalex.org/I53964585"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"E Yoles","raw_affiliation_strings":["Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel","institution_ids":["https://openalex.org/I53964585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113209228","display_name":"L. A. Wheeler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L A Wheeler","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5102841602","display_name":"Michal Schwartz","orcid":"https://orcid.org/0000-0003-4015-7507","observed_orcids":["https://orcid.org/0000-0003-4015-7507"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M Schwartz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":18.6088,"has_fulltext":false,"cited_by_count":242,"citation_normalized_percentile":{"value":0.99782711,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"40","issue":"1","first_page":"65","last_page":"73"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10250","display_name":"Glaucoma and retinal disorders","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10250","display_name":"Glaucoma and retinal disorders","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13796","display_name":"Neuroprotection in Cerebral Ischemia","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10483","display_name":"Nerve injury and regeneration","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9279999732971191},{"id":"https://openalex.org/keywords/optic-nerve-degeneration","display_name":"optic nerve degeneration","score":0.9440000057220459},{"id":"https://openalex.org/keywords/glaucoma","display_name":"glaucoma","score":0.777999997138977},{"id":"https://openalex.org/keywords/brimonidine","display_name":"brimonidine","score":0.9210000038146973},{"id":"https://openalex.org/keywords/clonidine","display_name":"clonidine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/timolol","display_name":"timolol","score":0.9980000257492065},{"id":"https://openalex.org/keywords/retinal-ganglion-cells","display_name":"retinal ganglion cells","score":0.8199999928474426},{"id":"https://openalex.org/keywords/optic-nerve-crush","display_name":"optic nerve crush","score":0.9210000038146973},{"id":"https://openalex.org/keywords/compound-action-potential","display_name":"compound action potential","score":0.9049999713897705},{"id":"https://openalex.org/keywords/rat-model","display_name":"rat model","score":0.49900001287460327}],"concepts":[{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.8142167329788208},{"id":"https://openalex.org/C2778190193","wikidata":"https://www.wikidata.org/wiki/Q577377","display_name":"Brimonidine","level":3,"score":0.7964684367179871},{"id":"https://openalex.org/C2780837183","wikidata":"https://www.wikidata.org/wiki/Q186029","display_name":"Optic nerve","level":2,"score":0.6787658333778381},{"id":"https://openalex.org/C2778073030","wikidata":"https://www.wikidata.org/wiki/Q413994","display_name":"Timolol","level":3,"score":0.6517233848571777},{"id":"https://openalex.org/C2781092963","wikidata":"https://www.wikidata.org/wiki/Q650050","display_name":"Intraocular pressure","level":2,"score":0.6248921155929565},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5539028644561768},{"id":"https://openalex.org/C2777624874","wikidata":"https://www.wikidata.org/wiki/Q927337","display_name":"Retinal ganglion cell","level":3,"score":0.4795657992362976},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4690205156803131},{"id":"https://openalex.org/C2778527774","wikidata":"https://www.wikidata.org/wiki/Q159701","display_name":"Glaucoma","level":2,"score":0.4134235084056854},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.402942419052124},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.32005417346954346}],"mesh":[{"descriptor_ui":"D000068438","descriptor_name":"Brimonidine Tartrate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000200","descriptor_name":"Action Potentials","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D000316","descriptor_name":"Adrenergic alpha-Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000317","descriptor_name":"Adrenergic alpha-Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001369","descriptor_name":"Axons","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002452","descriptor_name":"Cell Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002470","descriptor_name":"Cell Survival","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D003000","descriptor_name":"Clonidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004195","descriptor_name":"Disease Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007274","descriptor_name":"Injections, Intraperitoneal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009410","descriptor_name":"Nerve Degeneration","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D009410","descriptor_name":"Nerve Degeneration","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009410","descriptor_name":"Nerve Degeneration","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009410","descriptor_name":"Nerve Degeneration","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D009900","descriptor_name":"Optic Nerve","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D009900","descriptor_name":"Optic Nerve","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009901","descriptor_name":"Optic Nerve Diseases","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D009901","descriptor_name":"Optic Nerve Diseases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009901","descriptor_name":"Optic Nerve Diseases","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009901","descriptor_name":"Optic Nerve Diseases","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D011810","descriptor_name":"Quinoxalines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D012165","descriptor_name":"Retinal Ganglion Cells","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D012165","descriptor_name":"Retinal Ganglion Cells","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D013999","descriptor_name":"Timolol","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015016","descriptor_name":"Yohimbine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018341","descriptor_name":"Receptors, Adrenergic, alpha-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D020221","descriptor_name":"Optic Nerve Injuries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:9888428","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9888428","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigative ophthalmology & visual science","raw_type":"Journal Article"},{"id":"mag:71283047","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9888428","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W15838906","https://openalex.org/W18754481","https://openalex.org/W1491956741","https://openalex.org/W1605546054","https://openalex.org/W1974984138","https://openalex.org/W1976042967","https://openalex.org/W1990668296","https://openalex.org/W1991022487","https://openalex.org/W1998377120","https://openalex.org/W1998929064","https://openalex.org/W2006741513","https://openalex.org/W2007686281","https://openalex.org/W2011219129","https://openalex.org/W2023030735","https://openalex.org/W2039725423","https://openalex.org/W2048326920","https://openalex.org/W2050737894","https://openalex.org/W2059925177","https://openalex.org/W2060463791","https://openalex.org/W2065914444","https://openalex.org/W2074805758","https://openalex.org/W2088331394","https://openalex.org/W2096508436","https://openalex.org/W2139783494","https://openalex.org/W2159912845","https://openalex.org/W2169341893","https://openalex.org/W2409804882","https://openalex.org/W4296234132","https://openalex.org/W4313371117","https://openalex.org/W4323238066"],"related_works":["https://openalex.org/W169079711","https://openalex.org/W2182925317","https://openalex.org/W2560530479","https://openalex.org/W2086996191","https://openalex.org/W1964444582","https://openalex.org/W2063435261","https://openalex.org/W2435716697","https://openalex.org/W2986757937","https://openalex.org/W2168433798","https://openalex.org/W1532218365"],"abstract_inverted_index":{"PURPOSE:":[0],"The":[1,75],"neurodegenerative":[2],"progression":[3,270],"of":[4,21,28,39,59,70,72,103,105,117,141,181,189,209,232,245,251,260,267,271],"glaucoma":[5],"is":[6],"considered":[7],"to":[8,13,26,67,81,94,228],"be":[9,68],"related":[10],"not":[11,170],"only":[12],"primary":[14],"risk":[15],"factors":[16],"such":[17],"as":[18,257],"the":[19,33,36,40,60,95,106,118,133,150,190,207,246,269],"elevation":[20,71],"intraocular":[22,73,83,234],"pressure,":[23,84,235],"but":[24,169],"also":[25,86],"mediators":[27],"secondary":[29,56,272],"neuronal":[30,57,273],"degeneration.":[31,274],"In":[32,226],"present":[34],"study,":[35],"neuroprotective":[37,89,173,242],"activity":[38,90],"alpha2-adrenoreceptor":[41,167,236],"agonists":[42,183],"brimonidine,":[43],"AGN":[44],"191103,":[45],"and":[46,131,146],"clonidine":[47],"were":[48],"examined":[49,87],"in":[50,63,161,185,193,222],"an":[51],"animal":[52],"model":[53,250],"that":[54,263],"simulates":[55],"degeneration":[58,123],"optic":[61,120,158,248],"nerve":[62,159,249],"a":[64,186,241,258],"way":[65],"thought":[66],"independent":[69],"pressure.":[74],"beta-blocker":[76],"timolol,":[77,171,239],"currently":[78],"used":[79],"clinically":[80],"decrease":[82,192],"was":[85,109,124,136,217],"for":[88],"at":[91],"dosages":[92],"corresponding":[93],"effective":[96],"antihypertensive":[97],"dosage.":[98],"METHODS:":[99],"A":[100],"single":[101],"dose":[102],"each":[104,180],"tested":[107],"compounds":[108,262],"administered":[110,205],"intraperitoneally":[111],"immediately":[112,176],"after":[113,177,199,215],"partial":[114,252],"crush":[115,253],"injury":[116,178,216,254],"rat":[119,247],"nerve.":[121],"Secondary":[122],"measured":[125],"by":[126,139,148],"determining":[127],"injury-induced":[128,191],"deficits":[129],"with":[130,179,201],"without":[132],"drug.":[134],"This":[135],"achieved":[137],"electrophysiologically":[138],"measurement":[140],"compound":[142,194],"action":[143,195],"potential":[144,196],"amplitude,":[145],"morphometrically":[147],"counting":[149],"retrogradely":[151],"labeled":[152],"retinal":[153,210],"ganglion":[154,211],"cells,":[155],"representing":[156],"viable":[157],"axons,":[160],"wholemounted":[162],"retinas.":[163],"RESULTS:":[164],"All":[165],"three":[166,218],"agonists,":[168,237],"exhibited":[172],"effects.":[174],"Treatment":[175],"these":[182],"resulted":[184],"dose-dependent":[187],"attenuation":[188],"amplitude.":[197],"Moreover,":[198],"treatment":[200],"100":[202],"microg/kg":[203],"brimonidine":[204],"intraperitoneally,":[206],"loss":[208],"cells":[212],"2":[213],"weeks":[214],"times":[219],"lower":[220],"than":[221],"saline-treated":[223],"animals.":[224],"CONCLUSIONS:":[225],"addition":[227],"their":[229],"known":[230],"effect":[231],"lowering":[233],"unlike":[238],"exert":[240],"effect.":[243],"Use":[244],"can":[255],"serve":[256],"method":[259],"screening":[261],"are":[264],"potentially":[265],"capable":[266],"alleviating":[268]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":12},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2016-06-24T00:00:00"}